BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial
Dry Eye Disease
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Interventional
- Phase
- Phase 2
- Age range
- 18 years - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 20 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Documented diagnosis of dry eye disease
- Conjunctival hyperemia in both eyes, without clinical signs of infection or allergic conjunctivitis
Exclusion Criteria:
- Any active ocular disease
- Anticipated wearing of contact lenses during study
Additional criteria per protocol
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not applicable
- Masking
- No masking
BL1107 is sterile ophthalmic solution to be administered at varying concentrations
Not reported in this registry record.
Drug: BL1107
BL1107 DRUG
BL1107 topical ocular solution
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Primary Part 1: Proportion of participants with complete resolution in conjunctival hyperemia at 30 minutes, in each evaluated concentration of BL1107.
Time frame: Assessed at 30 minutes
Not reported in this registry record.
Primary Part 2: Proportion of participants with complete resolution in conjunctival hyperemia at 8 hours, in each evaluated concentration of BL1107
Time frame: Assessed at 8 hours
Not reported in this registry record.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Site 101Newport Beach, California, United StatesRecruiting
Study team and timeline
- Lead sponsor
- Bausch & Lomb Incorporated
- Study start
- Oct 19, 2026 Actual
- Primary completion
- 2027-02 Estimated
- Study completion
- 2027-02 Estimated
- First posted
- Aug 21, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Phase 2a Masked Trial to Identify the Lowest Effective Concentration of BL1107 for Conjunctival Hyperemia in Patients With Dry Eye Disease
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026